Bourdet DL - Search Results

1

Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.

Kenna JG, Taskar KS, Battista C, Bourdet DL, Brouwer KLR, Brouwer KR, Dai D, Funk C, Hafey MJ, Lai Y, Maher J, Pak YA, Pedersen JM, Polli JW, Rodrigues AD, Watkins PB, Yang K, Yucha RW; International Transporter Consortium. Kenna JG, et al. Among authors: bourdet dl. Clin Pharmacol Ther. 2018 Nov;104(5):916-932. doi: 10.1002/cpt.1222. Clin Pharmacol Ther. 2018. PMID: 30137645 Free PMC article. Review.

2

Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.

Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, Zamek-Gliszczynski MJ; International Transporter Consortium. Kalvass JC, et al. Among authors: bourdet dl. Clin Pharmacol Ther. 2013 Jul;94(1):80-94. doi: 10.1038/clpt.2013.34. Epub 2013 Feb 14. Clin Pharmacol Ther. 2013. PMID: 23588303 Review.

3

Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes.

McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KL, Kashuba AD. McRae MP, et al. Among authors: bourdet dl. J Pharmacol Exp Ther. 2006 Sep;318(3):1068-75. doi: 10.1124/jpet.106.102657. Epub 2006 May 23. J Pharmacol Exp Ther. 2006. PMID: 16720753

4

Next-Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development.

Roth SE, Avigan MI, Bourdet D, Brott D, Church R, Dash A, Keller D, Sherratt P, Watkins PB, Westcott-Baker L, Lentini S, Merz M, Ramaiah L, Ramaiah SK, Stanley AM, Marcinak J. Roth SE, et al. Clin Pharmacol Ther. 2020 Feb;107(2):333-346. doi: 10.1002/cpt.1571. Epub 2019 Sep 14. Clin Pharmacol Ther. 2020. PMID: 31314926 Free PMC article. Review.

5

Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat.

Bourdet DL, Tsuruda PR, Obedencio GP, Smith JA. Bourdet DL, et al. J Pharmacol Exp Ther. 2012 Apr;341(1):137-45. doi: 10.1124/jpet.111.188417. Epub 2012 Jan 10. J Pharmacol Exp Ther. 2012. PMID: 22235148

6

Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).

Bourdet DL, Pritchard JB, Thakker DR. Bourdet DL, et al. J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97. doi: 10.1124/jpet.105.091223. Epub 2005 Sep 1. J Pharmacol Exp Ther. 2005. PMID: 16141367

7

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.

Hey-Hadavi J, Seekins D, Palmer M, Coffey D, Caminis J, Abdullaev S, Patwardhan M, Tyler H, Raheja R, Stanley AM, Pineda-Salgado L, Bourdet DL, Andrade RJ, Hayashi PH, Dimick-Santos L, Rockey DC, Estilo A. Hey-Hadavi J, et al. Among authors: bourdet dl. Drug Saf. 2021 Jun;44(6):619-634. doi: 10.1007/s40264-021-01051-5. Epub 2021 Mar 16. Drug Saf. 2021. PMID: 33725335 Free PMC article. Review.

8

Safety, Pharmacokinetics, and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects.

Kanodia J, Lo A, Baldwin RM, Colley K, Zhou K, Bourdet DL. Kanodia J, et al. Among authors: bourdet dl. Clin Transl Sci. 2020 Nov;13(6):1307-1315. doi: 10.1111/cts.12831. Epub 2020 Aug 18. Clin Transl Sci. 2020. PMID: 32506827 Free PMC article. Clinical Trial.

9

Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells.

Bourdet DL, Pollack GM, Thakker DR. Bourdet DL, et al. Pharm Res. 2006 Jun;23(6):1178-87. doi: 10.1007/s11095-006-0204-y. Epub 2006 Jun 8. Pharm Res. 2006. PMID: 16741656

10

Saturable absorptive transport of the hydrophilic organic cation ranitidine in Caco-2 cells: role of pH-dependent organic cation uptake system and P-glycoprotein.

Bourdet DL, Thakker DR. Bourdet DL, et al. Pharm Res. 2006 Jun;23(6):1165-77. doi: 10.1007/s11095-006-0251-4. Epub 2006 Jun 8. Pharm Res. 2006. PMID: 16741655

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page